The catch: lawful and regulatory certainty is reduced. Retatrutide was never ever on the FDA drug shortage list (because it was never approved), so compounders offering it operate less than more tenuous lawful framing than people who managed semaglutide or tirzepatide in the course of the 2023–2024 shortages. Pricing may perhaps change as enforce… Read More